Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.

[1]  E. Wong,et al.  A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[2]  Y. Yoshioka,et al.  Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. , 2011, International journal of radiation oncology, biology, physics.

[3]  L. Brady,et al.  Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer , 2011, American journal of clinical oncology.

[4]  M. Santoro,et al.  Stereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer , 2010, Technology in cancer research & treatment.

[5]  J. Brooks,et al.  Patient-Reported Long-term Outcomes after Hypofractionated Stereotactic Radiotherapy for Low-risk Prostate Cancer: Evidence from a Prospective Trial , 2010 .

[6]  G. Gustafson,et al.  High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer , 2010, American journal of clinical oncology.

[7]  A. Katz.  CyberKnife Radiosurgery for Prostate Cancer , 2010, Technology in cancer research & treatment.

[8]  Anthony V D'Amico,et al.  The ‘CaP Calculator’: an online decision support tool for clinically localized prostate cancer , 2010, BJU international.

[9]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Santoro,et al.  Stereotactic body radiotherapy for organ-confined prostate cancer , 2010, BMC urology.

[11]  C. King,et al.  Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. , 2009, International journal of radiation oncology, biology, physics.

[12]  J. Friedland,et al.  Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer , 2009, Technology in cancer research & treatment.

[13]  R. Cowan,et al.  Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. , 2009, International journal of radiation oncology, biology, physics.

[14]  J. Brooks,et al.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. , 2009, International journal of radiation oncology, biology, physics.

[15]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[16]  C. Ménard,et al.  Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. , 2007, International journal of radiation oncology, biology, physics.

[17]  M. Meng,et al.  Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. , 2007, The Journal of urology.

[18]  A Daşu,et al.  Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[19]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[20]  J. Fowler,et al.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. , 2007, International journal of radiation oncology, biology, physics.

[21]  Patrick A. Kupelian,et al.  Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. , 2007, International journal of radiation oncology, biology, physics.

[22]  R. Holloway,et al.  Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. , 2006, International journal of radiation oncology, biology, physics.

[23]  Yoshiya Yamada,et al.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.

[24]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. J. Morris,et al.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Adler,et al.  CyberKnife Radiotherapy for Localized Prostate Cancer: Rationale and Technical Feasibility , 2003, Technology in cancer research & treatment.

[27]  V. Khoo,et al.  Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. , 2002, International journal of radiation oncology, biology, physics.

[28]  David J Brenner,et al.  What hypofractionated protocols should be tested for prostate cancer? , 2002, International journal of radiation oncology, biology, physics.

[29]  A. Swan,et al.  Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). , 1990, Urology.